|Bid||41.04 x 2200|
|Ask||41.08 x 1200|
|Day's Range||40.54 - 40.96|
|52 Week Range||34.52 - 42.36|
|Beta (3Y Monthly)||0.31|
|PE Ratio (TTM)||40.96|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||1.96 (4.87%)|
|1y Target Est||44.30|
Innoviva is the IBD Stock Of The Day as the biotech stock flirts with a breakout amid new uses for its GlaxoSmithKline-partnered medicines. Innoviva has several royalty deals with Glaxo.
Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.
On November 19, GlaxoSmithKline’s (GSK) stock price closed at $40.83, which represents ~1.21% growth from its close of $40.34 on November 16. GlaxoSmithKline’s stock price grew from $35.47 when the market closed on December 29, 2017, to $40.83 November 19, which reflects ~15% year-to-date growth.
On November 16, Merck’s (MRK) stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15. Merck’s stock price grew from $56.79 when the market opened on January 2 to $76.06 when the market closed on November 16, which representing ~34% year-to-date growth. On November 16, Merck hit its 52-week high of $76.25.
Many of the world's top drugmakers are not doing enough to provide medicines to poor countries, leaving big gaps in access to treatments in crucial disease areas, including cancer, according to a new report on Tuesday. The non-profit Access to Medicine Foundation (AMF) found companies overall were doing more than in the past to reach under-served populations, for example by setting lower prices for some drugs and improving transparency surrounding patents. What is more, research into urgently needed medicines for the developing world now relies on just a handful of companies, creating a fragile ecosystem where cutbacks by one player could have a significant impact on future supplies.
Novartis (NVS) obtains FDA approval for the label expansion of Promacta. The CHMP also issues a positive opinion for the label expansion of Kisqali.
Bausch Health’s (BHC) wholly owned subsidiary Ortho Dermatologics generated revenues of $177.0 million in the third quarter. In the third quarter, Ortho Dermatologics’ net revenues remained flat compared to the third quarter of 2017. Ortho Dermatologics witnessed ~1% YoY organic revenue growth.
Workplace is not a secret Facebook (FB) project, but the company rarely discusses this business. During Facebook’s third-quarter conference call last month, for instance, executives talked a lot about Instagram, WhatsApp, Messenger, and Oculus. It was only after the conference call that word came out that Facebook is planning a major shift for Workplace.
On Friday, the company said Imfinzi, its key lung cancer drug, had failed to deliver significant survival rates in late-stage, non-small cell lung cancer when used in combination with another of its immuno-oncology treatments. Rewind four years, and immuno-oncology – which enhances the body’s own ability to fight cancer – was a central pillar of Soriot’s defense. Concern about this pairing's performance in tests is one reason why it has taken until this year for AstraZeneca shares to climb above the 55 pounds-a-share proposal from Pfizer and stay there.
Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.
Nebula Genomics, devised by geneticist George Church to allow people to sell their DNA data for drug research and other uses, will provide complete DNA decoding at no charge for customers who answer a series of questions about their own health. The company begins offering its service Thursday and anyone is eligible to use it, Church said.
threatened to derail it, and the spectre of a “no deal” Brexit rose once more. Josh Hardie, deputy director-general of the CBI, said that, if the withdrawal agreement failing meant the UK crashing out of the EU without a deal, “it would be a disaster”.
After 10 years, GlaxoSmithKline and the Triangle Community Foundation have granted $4 million to local nonprofits as part of their annual Impact Awards.
“Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). While bronchodilation is recognised as the foundation of COPD therapy, many patients may continue to struggle with symptoms and exacerbations over time.
In the third quarter, Mylan (MYL) reported net sales of $1.01 billion from the North American market, which is a 14% decline on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the revenue drop was due to reduced sales volumes of existing products, including Epipen. According to Mylan’s third-quarter earnings conference call, the lower sales volumes in the third quarter were due to the timing of customers’ purchases and the restructuring and remediation program that was started at the Morgantown manufacturing facility in the second quarter.
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow ...